The application for the issuance of Corporate Bonds by Kangmei Pharmaceutical Co., Ltd. (“Kangmei Pharmaceutical”) amounting to not more than RMB2.5 billion has been passed and approved by the Securities Public Offering Examination and Approval Committee of China Securities Regulatory Commission (“CSRC”) on June 9, 2011.

The duly approved corporate bonds is issued with fixed interest bond with the term of no more than 7 years. After deducting the fees for the process of issuance, the funds is raised for the purposes to repay the bank loan amounting to RMB1.5 billion, and for the additional working capital.

Grandall Guangzhou Office has been retained as the Issuer's Counsel. Mr. CHENG Bing and Ms. LI Caixia are the key Grandall attorneys servicing Kangmei Pharmaceutical.

Click here to see more: Kangmei Pharmaceutical Co., Ltd.